"Blood Component Removal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
| Descriptor ID |
D001781
|
| MeSH Number(s) |
E02.120
|
| Concept/Terms |
Blood Component Removal- Blood Component Removal
- Blood Component Removals
- Component Removal, Blood
- Component Removals, Blood
- Removal, Blood Component
- Removals, Blood Component
- Pheresis
- Phereses
- Apheresis
- Aphereses
|
Below are MeSH descriptors whose meaning is more general than "Blood Component Removal".
Below are MeSH descriptors whose meaning is more specific than "Blood Component Removal".
This graph shows the total number of publications written about "Blood Component Removal" by people in this website by year, and whether "Blood Component Removal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blood Component Removal" by people in Profiles.
-
Shah L, Hooper DK, Okamura D, Wallace D, Moodalbail D, Gluck C, Koziell A, Zaritsky JJ. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr Nephrol. 2019 11; 34(11):2343-2350.
-
Graham BC, Pulido JS, Winters JL. Seeing is believing: A review of apheresis therapy in the treatment of ophthalmologic disease. J Clin Apher. 2018 Jun; 33(3):380-392.
-
Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, van Besien K, Cushing MM. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016 Apr; 56(4):893-8.
-
Flomenberg N, Comenzo RL, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):695-700.
-
Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood. 2008 Oct 15; 112(8):3036-47.
-
Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
-
Burch JW, Mair DC, Meny GM, Moroff G, Ching SS, Naidoff MA, Steuer ER, Loftus SA, Armstrong J, Clemons TE, Klein BE. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion. 2005 Nov; 45(11):1701-8.
-
Pulido JS, Winters J. Rheopheresis for macular degeneration: the data is not there yet to justify it. J Clin Apher. 2005 Oct; 20(3):168.
-
Pulido JS, Sanders D, Klingel R. Rheopheresis for age-related macular degeneration: clinical results and putative mechanism of action. Can J Ophthalmol. 2005 Jun; 40(3):332-40.
-
Klingel R, Fassbender C, Fischer I, Hattenbach L, G?mbel H, Pulido J, Koch F. Rheopheresis for age-related macular degeneration: a novel indication for therapeutic apheresis in ophthalmology. Ther Apher. 2002 Aug; 6(4):271-81.